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antimicrobial agents, occasionally including resistance to
colistin, hence, it can be considered the paradigm of noso-
comial multiresistant bacteria.24 14
arbapenems are still broadly active against E. coli, the inci-
ence of carbapenemases merits strict supervision mainly
n geographic areas where this resistance appears to be
ndemic in other species such as Klebsiella pneumoniae.
Other resistance traits have been described in E. coli
linical isolates as plasmid-mediated quinolone resistance
ue to qnr and aac(6’)-Ib-cr genes, and the efﬂux pump
epA. Moreover, production of plasmid 16S rRNA methy-
ases has recently drawn attention as a novel aminoglycoside
esistance mechanism in pathogenic gram-negative bacte-
ia including E. coli. It confers high-level resistance to all
minoglycosides that are currently available.
Multiresistance in E. coli affects almost all antimicrobial
amilies, it is easily transmitted through successful and vir-
lent clones and can be spread from and among not only
umans but animals and food. The role of continuous antimi-
robial pressure in this phenomenon is unquestionable and
equires control measures to curtail the spread and main-
enance of these multiresistant isolates with high likelihood
f causing serious and almost untreatable infections.
oi:10.1016/j.ijid.2010.02.1539
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Hospital-acquired and clinically-important Gram-
egative pathogens remain mostly Enterobacteriaceae,
seudomonas aeruginosa and Acinetobacter baumannii.
mong those Gram negatives, Klebsiella pneumoniae
emains an important source of hospital spread of multidrug
esistance. Wide-spectrum !-lactamases are increasingly
eported in Enterobacteriaceae being either clavulanic-
cid inhibited extended-spectrum !-lactamases (ESBLs) or
arbapenem-hydrolyzing !-lactamases (CHBLs). Although
rst reported in Klebsiella pneumoniae mostly from
980’s to 2000’s, ESBLs are developing rapidly among
ommunityacquired Escherichia coli. These novel ESBLs of
he CTX-M-type are reported worldwide with important
tructural and genetic diversity. Those ESBL genes may be
ransmitted from E. coli to K. pneumoniae providing a novel
ource of hospital-acquired multidrug-resistant K. pneumo-
iae since there are associated to other plasmid-mediated
esistance determinants. The CHBLs identiﬁed in Enter-
bacteriaceae are mostly metallo-!-lactamases (Ambler
lass B enzymes) of the VIM/IMP-types in hospital-acquired
. pneumoniae. The Ambler class A carbapenemases of
he KPC-type are also identifed mostly in K. pneumo-
iae, ﬁrst from the USA and then worldwide. The latest
eported CHBL in K. pneumoniae is OXA-48 mostly from
editerranean countries. All this carbapenemase producers
re difﬁcult to detect in a clinical laboratory and may
he source of multidrug resistance leading to therapeutic
eadend. K. pneumoniae will remain the most important
nterobacterial species as a source of multidrug resistance
n hospital-acquired Gram negative isolates.
oi:10.1016/j.ijid.2010.02.1540
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Acinetobacter baumannii are an important cause of noso-
omial infections mainly in patients in the intensive care
nits. In this presentation I will analyse the evolution of
ntimicrobial resistance, the molecular bases associated
ith the increase in antimicrobial resistance, the factors
ffecting multiresistance and the current treatment of
cinetobacter infections.
Antimicrobial resistance has steadily increased in the last
ecade. Nowadays A. baumannii clinical isolates resistant to
ll antimicrobial agents even to colistin (panresistant) have
een isolated in the nosocomial setting. Three major factors
avour the acquisition of multiresistance: 1. Intrinsic resis-
ance, mainly related to the interplay between decreased
ermeability (small number of porins) and constitutive
xpression of efﬂux pump(s) (AdeIJK, CraA); 2. Persistence
n the environment, in this sense, bioﬁlm-producing A. bau-
annii clinical isolates survive in inanimate surfaces longer
han those non-producing bioﬁlm. 3. Acquisition of genetic
lements. It has recently been shown that resistance islands
ith a variable composition of resistance determinants
nterspersed with transposons, integrons and other genetic
lements play an important role in the acquisition of mul-
iresistance. However, this is not an universal contributor
o multiresistance since target mutations, overexpression of
fﬂux pumps, and IS elements located upstream from some
esistance genes have also been found to be implicated in
ultiresistance. Although some clinical isolates are still sus-
eptible to carbapenems and colistin, and therefore these
ntimicrobial agents can continue to be used, few options
re available to treat infections caused by this microorgan-
sm. Tygecycline has been used to treat infections caused
y A. baumannii. However, emergence of resistance to this
ntimicrobial agent has been reported during treatment
hen this monotherapy.
This microorganism, albeit with slight differences
epending on the country, presents resistance to multipleoi:10.1016/j.ijid.2010.02.1542
